John Thomas Helgstrand1, Martin Andreas Røder2, Nina Klemann3, Birgitte Grønkær Toft4, Klaus Brasso5, Ben Vainer6, Peter Iversen7. 1. Copenhagen Prostate Cancer Center, Department of Urology, Copenhagen University Hospital, Rigshospitalet, University of Copenhagen, Ole maaløes vej 24, Section 7521, DK-2200 Copenhagen, Denmark. Electronic address: helgstrand1@me.com. 2. Copenhagen Prostate Cancer Center, Department of Urology, Copenhagen University Hospital, Rigshospitalet, University of Copenhagen, Ole maaløes vej 24, Section 7521, DK-2200 Copenhagen, Denmark. Electronic address: andreasroder@gmail.com. 3. Copenhagen Prostate Cancer Center, Department of Urology, Copenhagen University Hospital, Rigshospitalet, University of Copenhagen, Ole maaløes vej 24, Section 7521, DK-2200 Copenhagen, Denmark. Electronic address: ninakhp@gmail.com. 4. Department of Pathology, Copenhagen University Hospital, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen, Denmark. Electronic address: birgitte.groenkaer.toft@regionh.dk. 5. Copenhagen Prostate Cancer Center, Department of Urology, Copenhagen University Hospital, Rigshospitalet, University of Copenhagen, Ole maaløes vej 24, Section 7521, DK-2200 Copenhagen, Denmark. Electronic address: klaus.brasso@regionh.dk. 6. Department of Pathology, Copenhagen University Hospital, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen, Denmark. Electronic address: ben.vainer@regionh.dk. 7. Copenhagen Prostate Cancer Center, Department of Urology, Copenhagen University Hospital, Rigshospitalet, University of Copenhagen, Ole maaløes vej 24, Section 7521, DK-2200 Copenhagen, Denmark. Electronic address: peter.iversen@regionh.dk.
Abstract
BACKGROUND: The diagnostic characteristics of men who eventually die from prostate cancer (PCa) and the extent to which early diagnostic strategies have affected these characteristics are unclear. We aimed to investigate trends in survival and clinical presentation at diagnosis in men who eventually died from PCa. PATIENTS AND METHODS: Based on the national database, the Danish Prostate Cancer Registry, a nationwide population-based study of all 19,487 men who died from PCa in Denmark between 1995 and 2013 was conducted. Trends in median survival and trends in age, prostate-specific antigen (PSA), clinical stage, and Gleason score (GS) at diagnosis were analysed. RESULTS: A total of 46.9%, 16.8%, and 36.3% had metastatic (M+), locally advanced/lymph node positive (LaN+), and localised disease, respectively, at diagnosis. Only 0.15% had localised disease, GS ≤ 6 and PSA<10. Over time, the proportion of men with M+ disease at diagnosis decreased from 54.0-38.3% (p < 0.0001), whereas the proportion LaN + disease increased from 8.6-27.3% (p < 0.0001). The proportion of localised disease remained stable at 33.2-41.9%. Median survival increased 2.11 years from 1.88 (95% CI: 1.68-2.08) in 1995 to 3.99 (95% CI: 3.71-4.28) years in 2013, p < 0.0001. CONCLUSIONS: In a large population-based study, the results confirmed concurrent literature that the majority of men who eventually died from PCa had LaN+ or M+ disease at diagnosis. The proportion of men with M+ disease at diagnosis decreased significantly over time, parallelled by an increase in median survival. Taken together, this indicates a lead-time effect on survival, which presently, however, is not substantial enough to result in a reduced PCa-specific mortality.
BACKGROUND: The diagnostic characteristics of men who eventually die from prostate cancer (PCa) and the extent to which early diagnostic strategies have affected these characteristics are unclear. We aimed to investigate trends in survival and clinical presentation at diagnosis in men who eventually died from PCa. PATIENTS AND METHODS: Based on the national database, the Danish Prostate Cancer Registry, a nationwide population-based study of all 19,487 men who died from PCa in Denmark between 1995 and 2013 was conducted. Trends in median survival and trends in age, prostate-specific antigen (PSA), clinical stage, and Gleason score (GS) at diagnosis were analysed. RESULTS: A total of 46.9%, 16.8%, and 36.3% had metastatic (M+), locally advanced/lymph node positive (LaN+), and localised disease, respectively, at diagnosis. Only 0.15% had localised disease, GS ≤ 6 and PSA<10. Over time, the proportion of men with M+ disease at diagnosis decreased from 54.0-38.3% (p < 0.0001), whereas the proportion LaN + disease increased from 8.6-27.3% (p < 0.0001). The proportion of localised disease remained stable at 33.2-41.9%. Median survival increased 2.11 years from 1.88 (95% CI: 1.68-2.08) in 1995 to 3.99 (95% CI: 3.71-4.28) years in 2013, p < 0.0001. CONCLUSIONS: In a large population-based study, the results confirmed concurrent literature that the majority of men who eventually died from PCa had LaN+ or M+ disease at diagnosis. The proportion of men with M+ disease at diagnosis decreased significantly over time, parallelled by an increase in median survival. Taken together, this indicates a lead-time effect on survival, which presently, however, is not substantial enough to result in a reduced PCa-specific mortality.
Authors: Marc Casper Meineche Andersen; Hein Vincent Stroomberg; Klaus Brasso; John Thomas Helgstrand; Andreas Røder Journal: Diagnostics (Basel) Date: 2022-05-19
Authors: Lauren M Hurwitz; Corinne E Joshu; John R Barber; Anna E Prizment; Mara Z Vitolins; Miranda R Jones; Aaron R Folsom; Misop Han; Elizabeth A Platz Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-11-28 Impact factor: 4.254
Authors: Paul F Pinsky; Eric Miller; Philip Prorok; Robert Grubb; E David Crawford; Gerald Andriole Journal: BJU Int Date: 2018-11-02 Impact factor: 5.588
Authors: Andrew J Armstrong; Russell Z Szmulewitz; Daniel P Petrylak; Jeffrey Holzbeierlein; Arnauld Villers; Arun Azad; Antonio Alcaraz; Boris Alekseev; Taro Iguchi; Neal D Shore; Brad Rosbrook; Jennifer Sugg; Benoit Baron; Lucy Chen; Arnulf Stenzl Journal: J Clin Oncol Date: 2019-07-22 Impact factor: 44.544
Authors: Mads Dochedahl Winther; Gitte Kristensen; Hein Vincent Stroomberg; Kasper Drimer Berg; Birgitte Grønkær Toft; James D Brooks; Klaus Brasso; Martin Andreas Røder Journal: Diagnostics (Basel) Date: 2020-07-27
Authors: Magdalena Lycken; Oskar Bergengren; Linda Drevin; Hans Garmo; Marcus Westerberg; Elin Axén; Johan Stranne; Lars Holmberg; Anna Bill-Axelson Journal: Eur Urol Open Sci Date: 2022-05-28
Authors: Gerhardt Attard; Laura Murphy; Noel W Clarke; William Cross; Robert J Jones; Christopher C Parker; Silke Gillessen; Adrian Cook; Chris Brawley; Claire L Amos; Nafisah Atako; Cheryl Pugh; Michelle Buckner; Simon Chowdhury; Zafar Malik; J Martin Russell; Clare Gilson; Hannah Rush; Jo Bowen; Anna Lydon; Ian Pedley; Joe M O'Sullivan; Alison Birtle; Joanna Gale; Narayanan Srihari; Carys Thomas; Jacob Tanguay; John Wagstaff; Prantik Das; Emma Gray; Mymoona Alzoueb; Omi Parikh; Angus Robinson; Isabel Syndikus; James Wylie; Anjali Zarkar; George Thalmann; Johann S de Bono; David P Dearnaley; Malcolm D Mason; Duncan Gilbert; Ruth E Langley; Robin Millman; David Matheson; Matthew R Sydes; Louise C Brown; Mahesh K B Parmar; Nicholas D James Journal: Lancet Date: 2021-12-23 Impact factor: 79.321